Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
Status:
Completed
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of
irritability in patients with Huntington's disease. Two-thirds of all participants will
receive SRX246, while the other third will receive a placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Azevan Pharmaceuticals
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) NeuroNEXT Network